These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35238783)

  • 1. Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents.
    Giuffrè M; Masutti F; Maria Crosato I; Luzzati R; Saveria Crocè L
    Turk J Gastroenterol; 2022 Feb; 33(2):169-170. PubMed ID: 35238783
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Sustained Virologic Response to Direct-acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?
    Lok AS
    Clin Infect Dis; 2021 Mar; 72(5):787-788. PubMed ID: 32052046
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative changes of lipoprotein(a) in chronic hepatitis C patients achieving a sustained virological response by direct-acting antivirals.
    Okumura T; Joshita S; Sugiura A; Ota M; Umemura T
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):102011. PubMed ID: 36031100
    [No Abstract]   [Full Text] [Related]  

  • 5. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients.
    Nakajima T; Karino Y; Hige S; Suii H; Tatsumi R; Yamaguchi M; Arakawa T; Kuwata Y; Hasegawa T; Toyota J
    J Gastroenterol Hepatol; 2021 Feb; 36(2):367-375. PubMed ID: 32991760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
    Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
    Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
    J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
    Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
    Suraweera D; Saab EG; Tong MJ; Saab S
    Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
    Gonzalez HC; Gordon SC
    Gastroenterol Clin North Am; 2020 Jun; 49(2):301-314. PubMed ID: 32389364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    Nicolini LA; Menzaghi B; Molteni C; Vichi F; Cascio A; Parisini A; De Socio GV; Falasca K; Bonfanti P; Di Biagio A
    J Med Virol; 2022 Feb; 94(2):436-438. PubMed ID: 34499359
    [No Abstract]   [Full Text] [Related]  

  • 16. The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
    Park SJ; Kim AR; Choe WH; Kim JH; Yoo BC; Kwon SY
    Korean J Gastroenterol; 2018 Oct; 72(4):197-204. PubMed ID: 30419644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased and More Heterogeneous Gadoxetic Acid Uptake of the Liver Parenchyma after Hepatitis C Virus Eradication by Direct Antiviral Agent.
    Fujita N; Nishie A; Asayama Y; Ishigami K; Nakayama T; Ushijima Y; Kakihara D; Takayama Y; Morita K; Ishimatsu K; Takao S; Yoshizumi T; Furusyo N; Honda H
    Magn Reson Med Sci; 2020 Dec; 19(4):389-393. PubMed ID: 32051362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.